Literature DB >> 15338190

Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy.

Byung-Ryul Choi1, Myung-Ju Ahn, Woong Soo Lee, Tae-Hwan Kim, Sang-Cheol Bae, Jae-Bum Jun.   

Abstract

Acute leukemia is uncommonly seen with rheumatoid arthritis during or following treatment with low-dose methotrexate, a safe and effective treatment for the arthritic condition. We describe here a 68-year-old woman with rheumatoid arthritis who developed acute erythroleukemia during low-dose methotrexate therapy (total dose 1702.5 mg). This may be the first such case reported in the literature.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15338190     DOI： 10.1007/s00296-004-0502-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  9 in total

Review 1.  The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention.

Authors:  J E Karp; M A Smith
Journal:  Semin Oncol       Date:  1997-02       Impact factor: 4.929

2.  Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy.

Authors:  N S Rosenthal; D C Farhi
Journal:  Am J Clin Pathol       Date:  1996-11       Impact factor: 2.493

3.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

Review 4.  Toxicity of low dose methotrexate in rheumatoid arthritis.

Authors:  M E Weinblatt
Journal:  J Rheumatol Suppl       Date:  1985-12

5.  Acute myeloid leukemia in the setting of low dose weekly methotrexate therapy for rheumatoid arthritis.

Authors:  B Kolte; A N Baer; S N Sait; K L O'Loughlin; C C Stewart; M Barcos; M Wetzler; M R Baer
Journal:  Leuk Lymphoma       Date:  2001-07

6.  Adverse effects of low dose methotrexate therapy in rheumatoid arthritis.

Authors:  R J McKendry; P Dale
Journal:  J Rheumatol       Date:  1993-11       Impact factor: 4.666

7.  Temporal association between the use of methotrexate and development of leukemia in 2 patients with rheumatoid arthritis.

Authors:  L Dubin Kerr; K Troy; L Isola
Journal:  J Rheumatol       Date:  1995-12       Impact factor: 4.666

8.  The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis.

Authors:  J M Kremer; J K Lee
Journal:  Arthritis Rheum       Date:  1986-07

9.  Acute leukemia after low dose methotrexate therapy in a patient with rheumatoid arthritis.

Authors:  P Pointud; M Prudat; J M Peron
Journal:  J Rheumatol       Date:  1993-07       Impact factor: 4.666
  9 in total
  5 in total

Review 1.  Myeloid disorders after autoimmune disease.

Authors:  Prajwal C Boddu; Amer M Zeidan
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-07       Impact factor: 3.020

Review 2.  Acute myeloid leukemia developing in patients with autoimmune diseases.

Authors:  Safaa M Ramadan; Tamer M Fouad; Valentina Summa; Syed Kh Hasan; Francesco Lo-Coco
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

Review 3.  Rheumatic diseases and chronic myelogenous leukemia, presentation of four cases and review of the literature.

Authors:  Soner Senel; Emin Kaya; Ismet Aydogdu; M Ali Erkurt; Irfan Kuku
Journal:  Rheumatol Int       Date:  2006-01-11       Impact factor: 2.631

4.  A Fatal Case of Acute Myeloid Leukaemia-Methotrexate Related or Primary Autoimmune Disease Related: A Rare Case Report.

Authors:  Saurabh Agarwal; Nidhi Kaeley; Priyanka Gupta; Vibha Gupta; Rohan Bhatia
Journal:  J Clin Diagn Res       Date:  2016-03-01

5.  Acute myeloid leukemia with t(3;21)(q26.2;q22) developing following low-dose methotrexate therapy for rheumatoid arthritis and expressing two AML1/MDS1/EVI1 fusion proteins: A case report.

Authors:  Keisuke Tanaka; Gaku Oshikawa; Hiroki Akiyama; Shinya Ishida; Toshikage Nagao; Masahide Yamamoto; Osamu Miura
Journal:  Oncol Lett       Date:  2017-05-10       Impact factor: 2.967
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.